Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SAB
Key Highlights
- ➤Orchestra BioMed will host an R&D Day on November 12, 2026, in New York City
- ➤BACKBEAT Global Pivotal Trial evaluating AVIM Therapy has completed enrollment
- ➤Virtue Pivotal Trial evaluating Virtue SAB for coronary in-stent restenosis is enrolling patients
- ➤Medtronic (MDT) collaborates with Orchestra BioMed on AVIM Therapy development and commercialization
- ➤R&D Day will highlight clinical milestones and commercial potential for AVIM Therapy and Virtue SAB
Expert Statements
David Hochman, Chairman and Chief Executive Officer of Orchestra BioMed
“Orchestra BioMed leadership will be joined by key leading cardiologists to discuss the clinical and treatment burden associated with uncontrolled hypertension in pacemaker-indicated patients and restenosis in coronary stent interventions, as well as the potential for AVIM Therapy and Virtue SAB to address these unmet needs.”
NEW HOPE, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced it will host an R&D Day on November 12(th), 2026, at 3:00pm ET in New York City. The event will also be available via live webcast.
Orchestra BioMed leadership will be joined by key leading cardiologists to discuss the clinical and treatment burden associated with uncontrolled hypertension in pacemaker-indicated patients and restenosis in coronary stent interventions, as well as the potential for AVIM Therapy and Virtue SAB to address these unmet needs. The program will also highlight key upcoming clinical milestones and explore the commercial potential of AVIM Therapy and Virtue SAB.
Get started
Create a free account to read the full story.